Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
15 August, 2018 17:14 IST
Glenmark Pharm quarterly earnings fall 17.5%
Source: IRIS | 30 May, 2018, 10.54AM
Comments  |  Post Comment

Earnings per share for the quarter stood at Rs 5.37, registering 17.51% decline over previous year period.

''While FY 2018 was a challenging year mainly on account of pricing pressure in the U.S., our other key markets like Europe and India performed well on the back of new product launches. Even though we expect pricing pressure to persist, we are glad that FY 2019 has started on a positive note for us with approvals for some interesting products in the U.S.,'' said Glenn Saldanha, Chairman & MD, Glenmark Pharmaceuticals. (Q,N,C,F)* He further added, ''We recently filed our first New Drug Application (NDA) for Ryaltris in the U.S, which is a milestone in Glenmark's journey and marks our first step towards the transition to a specialty and innovative drugs company. We believe our strong R&D pipeline of novel assets will help propel growth in the long run.''

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
TCS named leader in KYC-AML BPO services by Everest Group - 14-Aug-2018 12:04
MCX to commence trading in rubber futures on August 16 - 14-Aug-2018 11:53
Cadila Healthcare acquires 51% stake in Windlas Healthcare - 13-Aug-2018 15:52
RCom re-instates bank guarantees of Rs 7.74 bn with DOT - 13-Aug-2018 12:08
Larsen & Tubro wins construction order worth Rs 30.28 bn - 13-Aug-2018 11:51
Tata Motors Group global wholesales at 92,639 in July'18 - 13-Aug-2018 10:32
Edelweiss Group to acquire two funds from Milestone Capital - 13-Aug-2018 10:01
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer